Vorapaxar
≥98%
- Product Code: 103411
CAS:
618385-01-6
| Molecular Weight: | 492.58 g./mol | Molecular Formula: | C₂₉H₃₃FN₂O₄ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
Vorapaxar is primarily used in the prevention of thrombotic cardiovascular events. It is specifically prescribed to reduce the risk of heart attack, stroke, and cardiovascular death in patients with a history of heart attack or peripheral arterial disease. The drug works by inhibiting platelet aggregation, which helps prevent the formation of blood clots that can lead to serious cardiovascular events. It is often used in combination with other antiplatelet therapies, such as aspirin or clopidogrel, to enhance its effectiveness. However, it is not recommended for patients with a history of stroke, transient ischemic attack, or intracranial hemorrhage, as it may increase the risk of bleeding. Vorapaxar is typically administered orally, and its use requires careful consideration of the patient’s medical history and risk factors for bleeding.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | ฿9,261.00 |
+
-
|
Vorapaxar
Vorapaxar is primarily used in the prevention of thrombotic cardiovascular events. It is specifically prescribed to reduce the risk of heart attack, stroke, and cardiovascular death in patients with a history of heart attack or peripheral arterial disease. The drug works by inhibiting platelet aggregation, which helps prevent the formation of blood clots that can lead to serious cardiovascular events. It is often used in combination with other antiplatelet therapies, such as aspirin or clopidogrel, to enhance its effectiveness. However, it is not recommended for patients with a history of stroke, transient ischemic attack, or intracranial hemorrhage, as it may increase the risk of bleeding. Vorapaxar is typically administered orally, and its use requires careful consideration of the patient’s medical history and risk factors for bleeding.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :